ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
1. iTeos Therapeutics is proposed to be sold for $10.047 per share.
2. Shareholders receive cash plus contingent rights depending on future net cash.
3. Legal investigation underway into adequacy of sale terms by former AG.
4. Contingent value rights could significantly increase total shareholder returns.
5. Concerns exist about undervaluation of the company in this sale.
The proposed sale price of $10.047 is higher than recent trading values. Historical cases show that acquisition prices often provide short-term premiums to shareholders.
How important is it?
The potential sale is critical for ITOS's future valuation and may reflect stronger underlying company value.
Why Short Term?
The price impact will likely be felt immediately due to the tender offer nature. Historical data indicates a quick investor response to acquisition offers.
NEW YORK and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of iTeos Therapeutics, Inc. (NASDAQGM:ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-itos/ to learn more.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163
